A Thorough Comparison of Sermorelin and hGH 

A Thorough Comparison of Sermorelin and hGH 


Scientists interested in learning how Sermorelin compares to hGH are encouraged to read to the end. Our specialists highlight important experimental data suggesting the potential of hGH and Sermorelin, which may include:


  • Boosting GH and IGF-1 serum levels 
  • Increasing weight regulation and loss 
  • Enhancing the development of muscular tissue 


We will also provide important details on the compounds’ development histories and profiles. Finally, we will give researchers the rundown on where they may consistently get high-quality Sermorelin for use in their labs. 


hGH: What is it?


An endogenous hormone, growth hormone (hGH) or somatotropin, is considered essential for development, cell division, metabolism, and tissue repair. Based on structural analysis, it comprises 191 amino acids. The American biotech firm Genentech was the first to use DNA-recombinant technology to recreate its precise amino acid structure in a controlled laboratory setting in 1981. Somatropin and recombinant hGH (rhGH) were terms used to describe the synthetic form of hGH, which was differentiated from natural somatotropin. Exogenous hGH  supplementation was devised to address growth hormone deficit (GHD). In GHD, the pituitary gland fails to secrete enough hGH, which causes symptoms such as metabolic problems in  cases of stunted development. 


Research has indicated that the bioidentical structure of rhGH may cause an increase in blood GH levels, reducing the symptoms of GHD in animal models. The compound subsequently gained research approval for additional exploration, including research in muscle wasting caused by HIV/AIDS or short-bowel syndrome (SBS) and pediatric short stature. Researchers provide the following data-based recommendations and research papers on growth hormone replacement theory and its indications for your information: 


Studies have suggested that daily exposure to hGH may contribute to the management of GHD symptoms as suggested in animal models observed over an extended period. Identical concentrations were evaluated in studies conducted on research models who did not have GHD. In short-term studies addressing muscle atrophy, hGH concentrations were given for three months to anima research models of HIV. 


 Sermorelin Peptide: What is it? 


Sermorelin is a synthetic form of growth hormone-releasing hormone (GHRH), also known as GRF 1-29. Sermorelin only contains the first 29 amino acids of the GHRH sequence, in contrast to endogenous GHRH, which consists of 44 amino acids. With all the features of complete GHRH (1-44) preserved, fragment 1-29 of GHRH is the critical region that may stimulate the anterior pituitary gland’s somatotroph cells to secrete growth hormone (GH). 


Native GH secretion is pulsatile and controlled by GHRH, a key regulator of growth, metabolism, and cell proliferation. When testing the peak GH response of the gland under stimulation, compounds such as Sermorelin are used since GH is produced in a pulsatile fashion and may be undetectable between pulses. 


Sermorelin peptide has also been well-studied in animal models of GHD and otherwise physiologically mature models. Although Sermorelin is not available beyond laboratory use and examination, it is available to approved researchers and academics for use in their work. 


hGH vs. Sermorelin: A Full Analysis 


Investigations purport that GH deficient animal models may be aided through hGH and Sermorelin exposure in preclinical studies. The effects of both on metabolic measures have also been investigated. Here, we compare and contrast Sermorelin with hGH replacement, outlining the main points that appear to affect their research potential and action mechanisms: 


  • hGH replacement appears to raise blood GH levels, even in animal models whose pituitary glands are completely dysfunctional, by distributing exogenous growth hormone. On the other hand, Sermorelin is hypothesized to depend on the pituitary gland’s efficiency as it appears to stimulate GH production there. 
  • Research indicates that Sermorelin’s half-life is around 10 minutes, long enough to trigger a peak in the organism’s natural GH production. Studies have suggested that an increase in GH production is expected to last around two hours after a presentation. Findings imply that serum GH levels may be increased for up to 12 hours after presentation, while hGH has a half-life of 3.4 hours. 
  • Alterations to serum GH levels: Large concentrations of hGH are more likely to cause adverse effects since these increases are concentration-dependent and may reach supraphysiological levels. Sermorelin, on the other hand, has been theorized to promote physiologically acceptable spontaneous GH production. 
  • Sermorelin and hGH replacement have been suggested to induce a change in the blood concentration of insulin-like growth factor-1 (IGF-1), the principal anabolic mediator of growth hormone.


Researchers interested in peptides for sale are encouraged to visit Core Peptides for the highest-quality research compounds available. Please note that none of the substances discussed in this paper have been approved for human or animal consumption and should, therefore, not be acquired or utilized by unlicensed individuals outside of contained research environments such as laboratories.




[i] Brinkman JE, Tariq MA, Leavitt L, et al. Physiology, Growth Hormone. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482141/


[ii] Flodh H. (1986). Human growth hormone produced with recombinant DNA technology: development and production. Acta paediatrica Scandinavica. Supplement, 325, 1–9. https://doi.org/10.1111/j.1651- 2227.1986.tb10356.x


[iii] Ayyar V. S. (2011). History of growth hormone therapy. Indian journal of endocrinology and metabolism, 15 Suppl 3(Suppl3), S162–S165. https://doi.org/10.4103/2230-8210.84852


[iv] Gupta V. (2011). Adult growth hormone deficiency. Indian journal of endocrinology and metabolism, 15 Suppl 3(Suppl3), S197–S202. https://doi.org/10.4103/2230-8210.84865


[v] Navarro, R., Dunn, J. D., Lee, P. A., Owens, G. M., & Rapaport, R. (2013). Translating clinical guidelines into practice: the effective and appropriate use of human growth hormone. The American journal of managed care, 19(15 Suppl), s281–s289


[vi] Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., Vance, M. L., & Endocrine Society (2011). Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. The Journal of clinical endocrinology and metabolism, 96(6), 1587–1609. https://doi.org/10.1210/jc.2011-0179


[vii] Liu, H., Bravata, D. M., Olkin, I., Nayak, S., Roberts, B., Garber, A. M., & Hoffman, A. R. (2007). Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of internal medicine, 146(2), 104–115. https://doi.org/10.7326/0003-4819- 146-2-200701160-00005


[viii] Schambelan, M., Mulligan, K., Grunfeld, C., Daar, E. S., LaMarca, A., Kotler, D. P., Wang, J., Bozzette, S. A., & Breitmeyer, J. B. (1996). Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Annals of internal medicine, 125(11), 873–882. https://doi.org/10.7326/0003-4819-125-11-199612010-00002